ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

16 Apr 2014
Price Change (% chg)

$1.41 (+11.02%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for IMGN.OQ


ImmunoGen, Inc. (ImmunoGen) develops targeted, antibody-based therapeutics for the treatment of cancer. ImmunoGen designs linkers that enable antibody-based therapeutics for the treatment of cancer agents to remain stably attached to the antibodies while in the blood stream and be released in their fully active form after... (more)


Beta: 1.95
Market Cap (Mil.): $1,217.41
Shares Outstanding (Mil.): 85.67
Dividend: --
Yield (%): --


  IMGN.OQ Industry Sector
P/E (TTM): -- 25.12 32.65
EPS (TTM): -0.36 -- --
ROI: -15.28 -2.94 19.01
ROE: -23.03 -12.86 19.78
Search Stocks

Immunogen halts trial of lung cancer drug; shares drop

- Immunogen Inc said it would discontinue a mid-stage trial of its experimental small-cell lung cancer drug following the death of a patient, sending its shares down 17 percent.

05 Nov 2013


Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
Provider: S&P Capital IQ Quantitative Report
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks